Accordingly, agents targeting the molecular participants in the Th2-high subtype (e.g., anti-IL-4, anti-IL-5, anti-IL-13, IgE blockers, and inhibitors of prostaglandin D2 (CRTH2) receptor) have recently been presented as potential drugs to treat asthma.11 Some of these targets are shown in Table 1. This evidence concerns the gene IGHE and asthma.